NCT04684238已完成3 期
A Randomised Active-controlled Study to Compare Efficacy & Safety of Inhaled Isoflurane Delivered by the AnaConDa-S (Anaesthetic Conserving Device) vs IV Midazolam for Sedation in Mechanically Ventilated Paediatric Patients 3-17 Years Old
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 94
- 试验地点
- 24
- 主要终点
- Percentage of Time of Adequately Maintained Sedation Depth up to 48 Hours (± 6 Hours)
研究概览
简要总结
This is a study to compare safety and efficacy of inhaled isoflurane delivered by the AnaConDa-S (Anaesthetic Conserving Device (ACD)) versus intravenous midazolam for sedation in mechanically ventilated children admitted to an intensive care unit.
详细描述
This is a phase III, multi-centre, prospective, randomized, active-controlled, assessor-blind study. Primary endpoint: percentage of time of adequately maintained sedation, in absence of rescue sedation, within the COMFORT-B interval (light, moderate, or deep sedation) prescribed at randomization, monitored every 2 hours for an expected minimum of 12 hours (up to 48 hours).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 3 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients at least 3 years to 17 (less than 18) years at the time of randomization, admitted to an ICU/with planned ICU admission.
- •Expected mechanical (invasive) ventilation and sedation for at least 12 hours.
- •Informed consent obtained from the patient, patient's legal guardian(s)
排除标准
- •Ongoing seizures requiring acute treatment.
- •Continuous sedation for more than 72 hours at time of randomization.
- •Less than 24 hours post cardiopulmonary resuscitation.
- •Uncompensated circulatory shock.
- •Known or suspected genetic susceptibility to malignant hyperthermia.
- •Patients with acute asthma or obstructive lung disease symptoms requiring treatment at inclusion.
- •Patient with tidal volume below 30 mL or above 800 mL.
- •Inability to perform reliable COMFORT-B assessment in the opinion of the Investigator
- •Patients with intracranial pressure (ICP) monitoring or with suspected increase in ICP
- •Patients with treatment-induced whole-body hypothermia.
- •Patients with pheochromocytoma.
- •Patients with prolonged QT interval or with significant risk for prolonged QT interval.
- •Patient not expected to survive next 48 hours or not committed to full medical care.
研究组 & 干预措施
Drug: Midazolam
Active Comparator
Midazolam for sedation in the ICU
干预措施: Midazolam (Drug)
Drug: Isoflurane
Experimental
Volatile for sedation in the ICU
干预措施: Isoflurane (Drug)
结局指标
主要结局
Percentage of Time of Adequately Maintained Sedation Depth up to 48 Hours (± 6 Hours)
时间窗: Minimum of 12 hours up to 48 hours (± 6 hours).
Percentage of time of adequately maintained sedation within the COMFORT-B interval (light, moderate or deep sedation) prescribed at randomisation, monitored every 2 h for a minimum of 12 h (up to 48 h ± 6 h)
次要结局
- Compare Ventilator-free Days(From start of study treatment up to 30 days)
- Evaluate the Frequency of Delirium(Patients admitted to the ICU ≥48 hours (including period prior to study enrolment) until the end of the 48-hour post study treatment monitoring or ICU discharge, whichever comes first.)
- Compare the Use of Opioids(Last 4 hours of study treatment compared to first 4 hours of study treatment after first blinded COMFORT-B assessment (at +2 h from start of study drug initiation).)
- Compare Time From End of Study Drug Administration to Extubation(From end of study drug administration to extubation or end of extubation attempt)
- Compare the Proportion of Time With Spontaneous Breathing(From initiation of study drug treatment to End of study treatment (up to 48h +/- 6h))
- Evaluate Haemodynamic Effect as Indicated by Need for Additional Inotropic/Vasopressor Agent(From start of study treatment to end of study treatment (up to 48h +/- 6h))
- Evaluate the Number of Patients With Withdrawal Symptom(From > 96 hours sedation (including pre-study sedation period) until the end of the 48-hour post study treatment monitoring or ICU discharge, whichever comes first.)
- Evaluate the Frequency of Neurological Symptoms or Psychomotor Dysfunction(During study treatment and up to 48 hours after discontinuation of isoflurane and midazolam)
- Compare the 30 Days/Hospital Mortality(From start of study treatment up to 30 days)
- Compare the Time in ICU/Hospital(From start of study treatment up to 30 days)
- Compare ICU-free Days(From start of study treatment up to 30 days)
研究者
研究点 (24)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU1)SedationNCT05312385Sedana Medical277
已完成
3 期
Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2)SedationNCT05327296Sedana Medical282
已完成
1 期
Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult VolunteersCystic Fibrosis (CF)NCT02605590Protalix18
已完成
不适用
Controller Medications in the Management of Bronchial AsthmaModerate to Severe Persistent Bronchial AsthmaNCT01055041Government Medical College, Bhavnagar50
已完成
3 期
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With AsthmaAsthmaNCT00394199SkyePharma AG357